|
- Toni Choueiri, MD Discusses Kidney Cancer JAVELIN 101 - Dana-Farber
Kidney cancer research at ASCO24: Final analysis in JAVELIN Renal 101 trial confirms the efficacy and manageable safety profile of avelumab plus axitinib versus sunitinib in patients with advanced kid
- Toni Choueiri, MD - Dana-Farber Cancer Institute | Boston, MA
Dr Toni K Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School
- Toni Choueiri: The Final Analysis of the JAVELIN Renal 101 trial
Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School
- Updated efficacy results from the JAVELIN Renal 101 trial . . . - PubMed
Background: The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma (aRCC) We report updated efficacy data from the second interim analysis
- Dr. Choueiri on the Subgroup Analysis of the JAVELIN Renal . . . - OncLive
In the trial, the frontline combination of avelumab (Bavencio) and axitinib (Inlyta) resulted in a 31% reduction in disease progression or death in patients with advanced RCC compared with
- Biomarker Search Reveals Unexpected Associations in Treatment of . . .
Scientists led by Toni Choueiri, MD, director of Dana-Farber’s Lank Center for Genitourinary Oncology, undertook a biomarker search using data from a phase 3 clinical trial called JAVELIN Renal 101
- Kidney Cancer JAVELIN 101: Toni Choueiri, MD | Dana-Farber Cancer . . .
Kidney cancer research at ASCO24: Final analysis in JAVELIN Renal 101 trial confirms the efficacy and manageable safety profile of avelumab plus axitinib ver
- Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell . . .
In this scoping review, we present many genomic biomarkers that have been developed and validated to varying degrees across the kidney cancer spectrum; however, no biomarker is used routinely in clinical practice for either prognostication or predicting a therapeutic response
|
|
|